Minimally-invasive
cellular procedures in a research-focused setting
BH Cellular Medicine is a physician‑led practice that evaluates emerging approaches in regenerative medicine. Our clinical services focus on individualized assessment, patient education, and participation in appropriate treatment pathways.
WELCOME
Welcome to BH Cellular Medicine. Our physicians provide consultations to discuss your medical history, current diagnoses, and conventional treatment options. In selected situations, and only where consistent with applicable US regulations, we may discuss the possibility of cellular procedures that use a patient’s own cells.
These cellular approaches are considered investigational for most diseases and conditions and are not approved by the US Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease. Any potential risks, uncertainties, and alternative options are reviewed in detail during a clinical consultation.
TECHNOLOGY THAT TRANSCENDS
Regenerative Medicine
After a comprehensive clinical evaluation, our physicians may consider procedures that use a patient’s own cells. These cells are processed under sterile conditions. These approaches are part of an evolving field of regenerative medicine and are the subject of ongoing research to better understand their safety profile and potential effects.
Any cellular procedures performed at BH Cellular Medicine are conducted in accordance with applicable US laws and regulations.
Regulatory Information & Commitment:
What Sets Us Apart
Under FDA’s regulations for human cells, tissues, and cellular and tissue‑based products (HCT/Ps), 21 CFR 1271.15(b) states: “You are not required to comply with the requirements of this part if you are an establishment that removes HCT/P’s from an individual and implants such HCT/P’s into the same individual during the same surgical procedure.
On December 9, 2025, the U.S. Food and Drug Administration’s Tissue Reference Group (TRG) sent an informal recommendation in response to a legal inquiry about our bone marrow aspirate concentrate (BMAC) procedure. In that letter, FDA staff stated:
"FDA’s Tissue Reference Group concluded that, based on the procedure exactly as described in the submission, our bone marrow aspirate concentrate procedure “appears to qualify for the same surgical procedure exception described in 21 CFR 1271.15(b).” This exception is a narrow exemption in FDA’s HCT/P regulations for autologous procedures where tissue is removed and re‑implanted into the same patient during the same surgical operation and remains essentially in its original form."(fda.gov)
Address
301 N. Canon Drive, Suite 305
Beverly Hills, CA 90210
Phone
424-490-BHCM (2426)